152:@0.085199:0.957873:0.109688:0.957873:0.109688:0.938882:0.085199:0.938882:0.007305:0.008593:0.008591
6:@0.038824:0.497523:0.060302:0.497523:0.060302:0.450045:0.038824:0.450045:0.021478
CHAPTER 6:@0.117647:0.067219:0.190817:0.067219:0.190817:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008716
would comprehensively identify genomic MRD targets from fusion genes and Ig/TCR :@0.117647:0.121273:0.857075:0.121273:0.857075:0.100900:0.117647:0.100900:0.014518:0.010820:0.011550:0.005182:0.011391:0.005501:0.008994:0.010843:0.017280:0.011071:0.007442:0.008948:0.011299:0.009039:0.011619:0.007601:0.005547:0.009633:0.008948:0.005182:0.009724:0.005501:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006506:0.009724:0.005501:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.005501:0.019608:0.013376:0.016139:0.005501:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.005501:0.006414:0.007442:0.010843:0.017645:0.005501:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.005501:0.009656:0.009039:0.011596:0.009039:0.007670:0.005501:0.009085:0.011596:0.011391:0.005501:0.006483:0.009861:0.007099:0.013057:0.014678:0.013376:0.004109
loci, in a rapid (e.g. less than one week), comprehensive and straightforward workflow :@0.117647:0.141852:0.856984:0.141852:0.856984:0.121479:0.117647:0.121479:0.005182:0.011276:0.008994:0.005341:0.004497:0.005593:0.005615:0.011756:0.005593:0.009291:0.005593:0.007898:0.008811:0.011071:0.005547:0.011391:0.005593:0.006939:0.008743:0.004497:0.009679:0.004497:0.005593:0.005182:0.009039:0.007531:0.007670:0.005593:0.006620:0.011391:0.009085:0.011756:0.005593:0.010845:0.011596:0.009039:0.005593:0.014518:0.009108:0.008948:0.010523:0.006939:0.004497:0.005593:0.008994:0.010843:0.017280:0.011071:0.007442:0.008948:0.011299:0.009039:0.011619:0.007604:0.005545:0.009633:0.009039:0.005593:0.009085:0.011596:0.011391:0.005593:0.007510:0.006437:0.007896:0.009087:0.005615:0.009930:0.011094:0.006437:0.006026:0.010843:0.008400:0.014723:0.009085:0.007442:0.011391:0.005593:0.014518:0.010843:0.007601:0.010706:0.005638:0.005570:0.010866:0.014723:0.004109
with minimal hands-on time requirements.:@0.117647:0.162431:0.482143:0.162431:0.482143:0.142058:0.117647:0.142058:0.014723:0.005273:0.006620:0.011459:0.004109:0.017645:0.005615:0.011756:0.005615:0.017574:0.009405:0.005250:0.004109:0.011391:0.009085:0.011596:0.011391:0.007670:0.007533:0.010843:0.011756:0.004109:0.006437:0.005615:0.017485:0.009039:0.004109:0.007442:0.009108:0.010706:0.011413:0.005615:0.007442:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.004497
We recently developed FUDGE -a targeted and directional nanopore sequencing as-:@0.117647:0.203588:0.852941:0.203588:0.852941:0.183215:0.117647:0.183215:0.018649:0.009039:0.006962:0.007442:0.009108:0.008994:0.009039:0.011391:0.006620:0.005182:0.009724:0.006962:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011505:0.009108:0.011391:0.006962:0.011276:0.016024:0.016501:0.015682:0.012098:0.006962:0.007533:0.009291:0.006962:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.006962:0.009085:0.011596:0.011391:0.006962:0.011391:0.005615:0.007442:0.009108:0.009108:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.006962:0.011687:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.006962:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.006962:0.009291:0.007738:0.007533
say- to rapidly identify recurrent fusion genes with unknown fusion gene partners and :@0.117647:0.224167:0.857091:0.224167:0.857091:0.203794:0.117647:0.203794:0.007944:0.008925:0.009724:0.007533:0.005182:0.006209:0.011048:0.005182:0.007898:0.008811:0.011071:0.005547:0.011525:0.005182:0.009724:0.005182:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006503:0.009724:0.005182:0.007442:0.009108:0.009106:0.011413:0.007807:0.007442:0.009039:0.011393:0.006437:0.005182:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.005182:0.009656:0.009039:0.011596:0.009039:0.007670:0.005182:0.014723:0.005273:0.006617:0.011459:0.005182:0.011413:0.011870:0.010706:0.011596:0.010866:0.014723:0.011756:0.005182:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.005182:0.009656:0.009039:0.011596:0.009039:0.005182:0.011368:0.009085:0.007964:0.006437:0.011598:0.009039:0.007624:0.007670:0.005182:0.009085:0.011596:0.011391:0.004109
extract the exact genomic breakpoint location . Based on this strategy, we developed :@0.117647:0.244745:0.857084:0.244745:0.857084:0.224373:0.117647:0.224373:0.009108:0.010089:0.006437:0.007898:0.009291:0.009108:0.006437:0.006346:0.006620:0.011299:0.009039:0.006346:0.009108:0.010089:0.009291:0.009108:0.006437:0.006346:0.009656:0.009039:0.011598:0.010843:0.017645:0.005547:0.008994:0.006346:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.006346:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.012130:0.004497:0.006346:0.012874:0.009291:0.007875:0.009108:0.011391:0.006346:0.010843:0.011756:0.006346:0.006620:0.011459:0.005615:0.007670:0.006346:0.007510:0.006437:0.007898:0.008811:0.006209:0.009039:0.010546:0.007989:0.004497:0.006346:0.014516:0.009039:0.006346:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011505:0.009108:0.011391:0.004109
30:@0.514003:0.237129:0.526167:0.237129:0.526167:0.225252:0.514003:0.225252:0.006082:0.006082
a nanopore sequencing assay ideally suited for the detection of personalized genomic :@0.117647:0.265324:0.857023:0.265324:0.857023:0.244951:0.117647:0.244951:0.009291:0.006232:0.011687:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.006232:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.006232:0.009291:0.007533:0.007944:0.008925:0.009724:0.006232:0.005547:0.011322:0.009288:0.009405:0.005387:0.005182:0.009724:0.006232:0.007510:0.011413:0.005273:0.006209:0.009108:0.011391:0.006232:0.006026:0.010843:0.007807:0.006232:0.006620:0.011299:0.009039:0.006232:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005545:0.010845:0.011756:0.006232:0.010840:0.006209:0.006232:0.011505:0.009039:0.007624:0.007875:0.010843:0.011687:0.009405:0.005250:0.005615:0.008834:0.009108:0.011391:0.006232:0.009656:0.009039:0.011596:0.010843:0.017645:0.005545:0.008994:0.004109
MRD targets from gene fusions and Ig/TCR rearrangements in lymphoid leukemias. We :@0.117647:0.285903:0.857089:0.285903:0.857089:0.265530:0.117647:0.265530:0.019608:0.013376:0.016139:0.003664:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.003675:0.006412:0.007442:0.010843:0.017645:0.003675:0.009656:0.009039:0.011596:0.009039:0.003664:0.006369:0.011413:0.007601:0.005547:0.010843:0.011619:0.007670:0.003664:0.009087:0.011596:0.011391:0.003664:0.006483:0.009861:0.007099:0.013057:0.014678:0.013376:0.003664:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011459:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.003675:0.005615:0.011756:0.003664:0.005182:0.009724:0.017280:0.011162:0.011299:0.010843:0.005547:0.011391:0.003664:0.005182:0.009131:0.011550:0.010274:0.009039:0.017645:0.005798:0.009291:0.007670:0.004497:0.003675:0.018649:0.009039:0.004109
retrospectively tested a panel of five :@0.117647:0.306482:0.421177:0.306482:0.421177:0.286109:0.117647:0.286109:0.007442:0.009131:0.006437:0.007442:0.010957:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.008948:0.005182:0.009724:0.004657:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.004657:0.009291:0.004657:0.011368:0.009085:0.011596:0.008948:0.005250:0.004657:0.010845:0.006209:0.004657:0.005684:0.005615:0.009633:0.009039:0.004109
KMT2A :@0.421752:0.306950:0.501692:0.306950:0.501692:0.284928:0.421752:0.284928:0.014906:0.019996:0.013765:0.010888:0.015157:0.005227
positive B-cell acute lymphoblastic leuke-:@0.502394:0.306482:0.852941:0.306482:0.852941:0.286109:0.502394:0.286109:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.004657:0.012646:0.007533:0.008994:0.008948:0.005387:0.005250:0.004657:0.009291:0.009108:0.011071:0.006209:0.009039:0.004657:0.005182:0.009724:0.017280:0.011162:0.011299:0.010957:0.010911:0.005433:0.009291:0.007510:0.006437:0.005547:0.008994:0.004657:0.005182:0.009131:0.011550:0.010272:0.009058:0.007533
mias (B-ALL) and five :@0.117647:0.327060:0.309508:0.327060:0.309508:0.306687:0.117647:0.306687:0.017645:0.005798:0.009291:0.007670:0.004360:0.006939:0.012646:0.007533:0.014929:0.011619:0.011619:0.006939:0.004360:0.009085:0.011596:0.011391:0.004360:0.005684:0.005615:0.009635:0.009039:0.004109
SIL-TAL1 :@0.309757:0.327529:0.403301:0.327529:0.403301:0.305507:0.309757:0.305507:0.010500:0.007647:0.012030:0.007624:0.012326:0.015157:0.012144:0.010888:0.005227
positive T-cell acute lymphoblastic leukemia (T-ALL) :@0.403620:0.327060:0.857051:0.327060:0.857051:0.306687:0.403620:0.306687:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.004360:0.011801:0.007533:0.008994:0.008948:0.005387:0.005250:0.004360:0.009291:0.009108:0.011071:0.006209:0.009039:0.004360:0.005182:0.009724:0.017280:0.011162:0.011299:0.010957:0.010911:0.005433:0.009291:0.007510:0.006437:0.005547:0.008994:0.004360:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.004360:0.006825:0.011801:0.007533:0.014929:0.011619:0.011619:0.006939:0.004109
samples. We show the capability of the assay to comprehensively target fusion genes as :@0.117647:0.347639:0.857029:0.347639:0.857029:0.327266:0.117647:0.327266:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.005296:0.018649:0.009039:0.005296:0.007556:0.011302:0.010866:0.014723:0.005296:0.006620:0.011299:0.009039:0.005296:0.009108:0.008811:0.011368:0.009108:0.010820:0.005750:0.005250:0.005273:0.006437:0.009724:0.005296:0.010843:0.006209:0.005296:0.006617:0.011302:0.009039:0.005296:0.009291:0.007533:0.007944:0.008925:0.009724:0.005296:0.006209:0.011048:0.005296:0.008994:0.010843:0.017280:0.011071:0.007442:0.008948:0.011299:0.009039:0.011619:0.007601:0.005547:0.009633:0.008948:0.005182:0.009724:0.005296:0.006549:0.009087:0.007624:0.009656:0.009131:0.006437:0.005296:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.005296:0.009656:0.009039:0.011596:0.009039:0.007670:0.005296:0.009291:0.007670:0.004109
well as the Ig and TCR loci and to detect the sequence of genomic breakpoints for use :@0.117647:0.368218:0.857029:0.368218:0.857029:0.347845:0.117647:0.347845:0.014518:0.008948:0.005387:0.005250:0.005456:0.009291:0.007670:0.005456:0.006620:0.011299:0.009039:0.005456:0.006483:0.009861:0.005456:0.009085:0.011596:0.011391:0.005456:0.013057:0.014678:0.013376:0.005456:0.005182:0.011276:0.008994:0.005615:0.005456:0.009085:0.011596:0.011391:0.005456:0.006209:0.011048:0.005456:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005456:0.006620:0.011299:0.009039:0.005456:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009039:0.005456:0.010843:0.006209:0.005456:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.005456:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.005456:0.006029:0.010840:0.007807:0.005456:0.011413:0.007875:0.009039:0.004109
in the subsequent design of MRD assays. We confirm 86% of the MRD targets that were :@0.117647:0.388796:0.857007:0.388796:0.857007:0.368423:0.117647:0.368423:0.005615:0.011756:0.004246:0.006620:0.011299:0.009039:0.004246:0.007510:0.011345:0.010934:0.007875:0.009108:0.010703:0.011347:0.009039:0.011391:0.006437:0.004246:0.011322:0.009039:0.007601:0.005615:0.009861:0.011756:0.004246:0.010843:0.006209:0.004246:0.019608:0.013376:0.016139:0.004246:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004497:0.004246:0.018649:0.009039:0.004246:0.008994:0.010843:0.011756:0.005684:0.005684:0.007807:0.017645:0.004246:0.010432:0.010432:0.015043:0.004246:0.010843:0.006209:0.004246:0.006620:0.011299:0.009039:0.004246:0.019608:0.013376:0.016139:0.004246:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.004246:0.006620:0.011391:0.008811:0.006437:0.004246:0.014518:0.009039:0.007442:0.009039:0.004109
diagnostically determined for these patients and identify an additional 32 potential pa-:@0.117647:0.409375:0.852941:0.409375:0.852941:0.389002:0.117647:0.389002:0.011391:0.005798:0.009199:0.009861:0.011596:0.010957:0.007510:0.006437:0.005547:0.009108:0.009405:0.005385:0.005182:0.009724:0.004931:0.011322:0.009131:0.006209:0.009039:0.007807:0.017645:0.005615:0.011594:0.009108:0.011391:0.004931:0.006026:0.010843:0.007807:0.004931:0.006617:0.011302:0.009039:0.007873:0.009039:0.004931:0.011365:0.008813:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004931:0.009085:0.011596:0.011391:0.004931:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006506:0.009724:0.004931:0.009085:0.011756:0.004931:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.004931:0.010432:0.010432:0.004931:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009402:0.005250:0.004931:0.011368:0.009297:0.007533
tient-specific MRD targets - all within 48 hours. :@0.117647:0.429954:0.522405:0.429954:0.522405:0.409581:0.117647:0.409581:0.006437:0.005547:0.009039:0.011391:0.006437:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005613:0.008994:0.004109:0.019608:0.013376:0.016139:0.004109:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.004109:0.007533:0.004109:0.009402:0.005387:0.005250:0.004109:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004109:0.010432:0.010432:0.004109:0.011299:0.010820:0.011413:0.007622:0.007670:0.004497:0.004109
Results:@0.117647:0.489087:0.197715:0.489087:0.197715:0.460976:0.117647:0.460976:0.013103:0.010895:0.012144:0.013015:0.008541:0.010226:0.012144
KMT2A and SIL-TAL1 assay design:@0.117647:0.535021:0.389549:0.535021:0.389549:0.511861:0.117647:0.511861:0.010708:0.014817:0.008541:0.009861:0.010309:0.003735:0.010558:0.011679:0.011231:0.003982:0.010409:0.004856:0.007446:0.005877:0.007520:0.010558:0.008068:0.005229:0.003735:0.010409:0.010409:0.010260:0.009064:0.010060:0.003984:0.011231:0.009214:0.010409:0.004856:0.011206:0.011679
We previously developed FUDGE , a targeted and directional nanopore sequencing :@0.117647:0.578561:0.857057:0.578561:0.857057:0.558188:0.117647:0.558188:0.018649:0.009039:0.006506:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.006506:0.011322:0.009334:0.009635:0.008946:0.005182:0.010822:0.011502:0.009108:0.011391:0.006506:0.011276:0.016024:0.016504:0.015682:0.012098:0.018243:0.004497:0.006506:0.009291:0.006506:0.006551:0.009085:0.007626:0.009656:0.009131:0.006207:0.009108:0.011391:0.006506:0.009085:0.011596:0.011391:0.006506:0.011391:0.005615:0.007442:0.009108:0.009108:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.006506:0.011687:0.009087:0.011596:0.010820:0.011502:0.010843:0.007444:0.009039:0.006506:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004109
403:@0.411607:0.570945:0.429852:0.570945:0.429852:0.559068:0.411607:0.559068:0.006082:0.006082:0.006082
assay,  to  identify  recurrent  fusion  genes  irrespective  of  fusion  partner  and  genomic :@0.117647:0.599140:0.857050:0.599140:0.857050:0.578767:0.117647:0.578767:0.009291:0.007533:0.007944:0.008925:0.007989:0.004497:0.004109:0.004027:0.006211:0.011048:0.004109:0.004027:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006506:0.009724:0.004109:0.004027:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.004109:0.004029:0.006366:0.011413:0.007601:0.005547:0.010843:0.011756:0.004109:0.004029:0.009656:0.009039:0.011596:0.009039:0.007670:0.004109:0.004027:0.005615:0.007807:0.007442:0.009039:0.007512:0.011502:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.004109:0.004029:0.010843:0.006209:0.004109:0.004027:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.004109:0.004027:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007807:0.004109:0.004029:0.009085:0.011596:0.011391:0.004109:0.004029:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004109
breakpoint position. We here apply FUDGE to a panel of KMT2A and SIL-TAL1 fu-:@0.117647:0.619719:0.852941:0.619719:0.852941:0.599346:0.117647:0.599346:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.006232:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.010843:0.011756:0.004497:0.006232:0.018649:0.009039:0.006232:0.011299:0.009039:0.007442:0.009039:0.006232:0.008811:0.011048:0.011162:0.005182:0.009724:0.006232:0.011276:0.016024:0.016504:0.015682:0.012098:0.006232:0.006209:0.011048:0.006232:0.009291:0.006232:0.011368:0.009085:0.011596:0.008948:0.005250:0.006232:0.010843:0.006209:0.006232:0.014541:0.019608:0.013354:0.010432:0.014929:0.006232:0.009085:0.011596:0.011391:0.006232:0.009770:0.007259:0.011391:0.007533:0.011710:0.014929:0.011619:0.010432:0.006232:0.006369:0.011502:0.007533
sion-positive B-ALL and T-ALL patient samples, respectively, to identify unique ge-:@0.117647:0.640298:0.852941:0.640298:0.852941:0.619925:0.117647:0.619925:0.007601:0.005547:0.010843:0.011756:0.007533:0.011505:0.010957:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.007647:0.012646:0.007533:0.014929:0.011619:0.011619:0.007647:0.009085:0.011598:0.011391:0.007647:0.011801:0.007533:0.014929:0.011619:0.011619:0.007647:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007647:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004497:0.007647:0.007442:0.009039:0.007512:0.011502:0.009108:0.009108:0.006437:0.005547:0.009633:0.008948:0.005182:0.007989:0.004497:0.007647:0.006209:0.011048:0.007647:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006506:0.009724:0.007647:0.011413:0.011756:0.005547:0.010706:0.011345:0.009039:0.007647:0.009656:0.008966:0.007533
nomic breakpoint junctions which may serve as suitable biomarkers for subsequent :@0.117647:0.660876:0.857050:0.660876:0.857050:0.640503:0.117647:0.640503:0.011596:0.010843:0.017645:0.005547:0.008994:0.007784:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.007784:0.004953:0.011413:0.011596:0.009108:0.006437:0.005547:0.010843:0.011619:0.007670:0.007784:0.014789:0.011459:0.005547:0.008765:0.011459:0.007784:0.017577:0.008928:0.009724:0.007784:0.007873:0.009039:0.008400:0.009633:0.009039:0.007784:0.009291:0.007670:0.007784:0.007510:0.011413:0.005273:0.006551:0.009108:0.010911:0.005182:0.009039:0.007784:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.007784:0.006026:0.010843:0.007807:0.007784:0.007512:0.011345:0.010934:0.007873:0.009108:0.010706:0.011345:0.009039:0.011391:0.006437:0.004109
quantitative PCR-based MRD testing with breakpoint-spanning primers (:@0.117647:0.681455:0.751387:0.681455:0.751387:0.661082:0.117647:0.661082:0.010706:0.011596:0.009085:0.011391:0.006437:0.005273:0.006551:0.008811:0.006437:0.005547:0.009633:0.009039:0.006026:0.012167:0.014678:0.012349:0.007533:0.011117:0.009291:0.007875:0.009108:0.011391:0.006026:0.019608:0.013376:0.016139:0.006026:0.006207:0.009039:0.007512:0.006437:0.005615:0.011459:0.009861:0.006026:0.014723:0.005273:0.006620:0.011459:0.006026:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.007533:0.007510:0.011368:0.009085:0.011756:0.011756:0.005615:0.011459:0.009861:0.006026:0.011071:0.007807:0.005615:0.017485:0.009039:0.007624:0.007670:0.006026:0.006939
Figure 1A:@0.751423:0.681455:0.841497:0.681455:0.841497:0.660322:0.751423:0.660322:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.005889:0.010911:0.015089
). :@0.841505:0.681455:0.857050:0.681455:0.857050:0.661082:0.841505:0.661082:0.006939:0.004497:0.004109
FUDGE couples target-selected and strand-specific CRISPR/Cas9 activity, which fa-:@0.117647:0.702034:0.852941:0.702034:0.852941:0.681661:0.117647:0.681661:0.011276:0.016024:0.016504:0.015682:0.012098:0.007647:0.008994:0.010820:0.011071:0.011162:0.005182:0.009039:0.007670:0.007647:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007533:0.007875:0.008948:0.005182:0.009108:0.009106:0.006211:0.009106:0.011391:0.007647:0.009085:0.011596:0.011391:0.007647:0.007510:0.006437:0.007898:0.009085:0.011596:0.011391:0.007533:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005613:0.008994:0.007647:0.014678:0.013376:0.007259:0.009770:0.011664:0.013376:0.007099:0.014974:0.009291:0.007670:0.010432:0.007647:0.009291:0.009108:0.006437:0.005547:0.009838:0.005273:0.006437:0.007989:0.004497:0.007647:0.014792:0.011459:0.005547:0.008765:0.011459:0.007647:0.006209:0.009338:0.007533
cilitates  enrichment by selective sequencing adapter  ligation, to  long-read real-time :@0.117647:0.722612:0.857112:0.722612:0.857112:0.702239:0.117647:0.702239:0.008994:0.005752:0.005250:0.005273:0.006551:0.008809:0.006211:0.009039:0.007670:0.004109:0.004394:0.009039:0.011756:0.007807:0.005547:0.008765:0.011459:0.017485:0.009039:0.011391:0.006437:0.008514:0.010843:0.009724:0.008514:0.007875:0.008948:0.005182:0.009108:0.009106:0.006437:0.005547:0.009633:0.009039:0.008514:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.008514:0.009291:0.011571:0.008813:0.011046:0.006211:0.009039:0.007807:0.004109:0.004394:0.005250:0.005615:0.009861:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.008514:0.006209:0.011048:0.004109:0.004394:0.005182:0.010843:0.011461:0.009861:0.007533:0.007442:0.009291:0.009291:0.011391:0.008514:0.007442:0.009291:0.009405:0.005250:0.007533:0.006437:0.005615:0.017488:0.009039:0.004109
nanopore sequencing (:@0.117647:0.743191:0.313590:0.743191:0.313590:0.722818:0.117647:0.722818:0.011687:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.005695:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.005615:0.011459:0.009861:0.005693:0.006939
Supplementary Figure 1:@0.313590:0.743191:0.530376:0.743191:0.530376:0.722058:0.313590:0.722058:0.010455:0.011893:0.011733:0.011779:0.005935:0.009268:0.018102:0.009268:0.012053:0.007053:0.009656:0.009359:0.009998:0.005570:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.005570:0.010911
). KMT2A, a recurrent fusion partner :@0.530371:0.743191:0.857050:0.743191:0.857050:0.722818:0.530371:0.722818:0.006939:0.004497:0.005693:0.014541:0.019608:0.013354:0.010432:0.014929:0.004497:0.005693:0.009291:0.005695:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005693:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.005695:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007807:0.004109
gene in leukemias, has been reported with >130 different fusion gene configurations. :@0.117647:0.763770:0.857141:0.763770:0.857141:0.743397:0.117647:0.743397:0.009656:0.009039:0.011596:0.009039:0.006551:0.005615:0.011756:0.006551:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.007670:0.004497:0.006551:0.011391:0.009291:0.007670:0.006551:0.011254:0.009108:0.009039:0.011756:0.006551:0.007442:0.009131:0.011505:0.010843:0.007967:0.006209:0.009108:0.011391:0.006551:0.014723:0.005273:0.006620:0.011459:0.006551:0.011550:0.010432:0.010432:0.010432:0.006551:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.006551:0.006366:0.011413:0.007604:0.005547:0.010843:0.011756:0.006551:0.009656:0.009039:0.011596:0.009039:0.006551:0.008994:0.010843:0.011756:0.005684:0.005684:0.009861:0.011413:0.007896:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004497:0.004109
Furthermore, there are two clusters within the KMT2A gene spanning approximatively :@0.117647:0.784348:0.857032:0.784348:0.857032:0.763976:0.117647:0.763976:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004748:0.006620:0.011299:0.009039:0.007442:0.009039:0.004748:0.009085:0.007442:0.009039:0.004748:0.006437:0.014518:0.011048:0.004748:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.007624:0.007670:0.004748:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004748:0.006620:0.011302:0.009039:0.004748:0.014541:0.019608:0.013354:0.010432:0.014929:0.004748:0.009656:0.009039:0.011596:0.009039:0.004748:0.007510:0.011368:0.009085:0.011756:0.011756:0.005615:0.011459:0.009861:0.004748:0.008811:0.011048:0.011071:0.007442:0.010820:0.010089:0.005615:0.017577:0.008811:0.006437:0.005547:0.009633:0.008948:0.005182:0.009724:0.004109
12.4 kb where previous breakpoints have been reported . Therefore, we designed two :@0.117647:0.804927:0.857019:0.804927:0.857019:0.784554:0.117647:0.784554:0.010432:0.010432:0.004497:0.010432:0.005387:0.010272:0.011025:0.005387:0.014789:0.011299:0.009039:0.007442:0.009039:0.005387:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007670:0.005387:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.005387:0.011391:0.008925:0.009633:0.009039:0.005387:0.011254:0.009108:0.009039:0.011756:0.005387:0.007442:0.009131:0.011505:0.010843:0.007967:0.006209:0.009108:0.011391:0.018299:0.004497:0.005387:0.011470:0.011311:0.009039:0.007442:0.009039:0.006026:0.010843:0.007442:0.008743:0.004497:0.005387:0.014518:0.009039:0.005387:0.011322:0.009039:0.007601:0.005615:0.009861:0.011596:0.009108:0.011391:0.005387:0.006437:0.014518:0.011048:0.004109
387:@0.591674:0.797311:0.609919:0.797311:0.609919:0.785434:0.591674:0.785434:0.006082:0.006082:0.006082
crRNAs (crK-e7 and crK-e19) targeting these two main breakpoint clusters (:@0.117647:0.825506:0.754877:0.825506:0.754877:0.805133:0.117647:0.805133:0.008994:0.007807:0.013376:0.015408:0.014586:0.007670:0.003789:0.006939:0.008994:0.007807:0.014541:0.007533:0.009039:0.010432:0.003789:0.009085:0.011596:0.011391:0.003789:0.008994:0.007807:0.014541:0.007533:0.009039:0.010432:0.010432:0.006939:0.003789:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.005615:0.011459:0.009861:0.003789:0.006620:0.011299:0.009039:0.007875:0.009039:0.003789:0.006437:0.014518:0.011048:0.003789:0.017577:0.009085:0.005615:0.011756:0.003789:0.010820:0.007442:0.009291:0.009402:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.003789:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.007624:0.007670:0.003789:0.006939
Figure 1B:@0.754934:0.825506:0.841504:0.825506:0.841504:0.804373:0.754934:0.804373:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.003709:0.010911:0.013765
). :@0.841505:0.825506:0.857050:0.825506:0.857050:0.805133:0.841505:0.805133:0.006939:0.004497:0.004109
SIL-TAL1, a specific and recurrent rearrangement between SIL and TAL1 adjacently lo-:@0.117647:0.846085:0.852941:0.846085:0.852941:0.825712:0.117647:0.825712:0.009770:0.007259:0.011391:0.007533:0.011710:0.014929:0.011619:0.010432:0.004497:0.004291:0.009291:0.004291:0.007512:0.011505:0.009106:0.008994:0.005615:0.005684:0.005615:0.008994:0.004291:0.009085:0.011596:0.011391:0.004291:0.007442:0.009106:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.004291:0.007442:0.009291:0.009085:0.007807:0.007898:0.009085:0.011461:0.009656:0.009039:0.017485:0.009039:0.011391:0.006437:0.004291:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.004291:0.009768:0.007259:0.011619:0.004291:0.009087:0.011596:0.011391:0.004291:0.011710:0.014929:0.011619:0.010432:0.004291:0.009291:0.011046:0.005273:0.009291:0.008994:0.009039:0.011391:0.006620:0.005182:0.009724:0.004291:0.005184:0.011046:0.007533
cated on chromosome 1, is induced through a site-specific deletion between the genes :@0.117647:0.866663:0.857068:0.866663:0.857068:0.846290:0.117647:0.846290:0.009108:0.008811:0.006209:0.009108:0.011391:0.005593:0.010843:0.011756:0.005593:0.008765:0.011459:0.007442:0.010843:0.017485:0.010957:0.007875:0.010843:0.017485:0.009039:0.005593:0.010432:0.004497:0.005593:0.005615:0.007670:0.005593:0.005615:0.011596:0.011046:0.011347:0.008994:0.009106:0.011391:0.005593:0.006617:0.011459:0.007442:0.010822:0.011413:0.009927:0.011459:0.005593:0.009291:0.005593:0.007601:0.005273:0.006209:0.009039:0.007533:0.007510:0.011502:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.005593:0.011322:0.008948:0.005182:0.009131:0.006437:0.005547:0.010843:0.011756:0.005593:0.011251:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.005593:0.006620:0.011299:0.009039:0.005593:0.009658:0.009039:0.011596:0.009039:0.007670:0.004109
of approximately 85 kb or chromosomal translocations in approximately 20% of T-ALL :@0.117647:0.887242:0.857100:0.887242:0.857100:0.866869:0.117647:0.866869:0.010843:0.006209:0.004543:0.008811:0.011048:0.011071:0.007442:0.010820:0.010089:0.005615:0.017577:0.008811:0.006209:0.008948:0.005182:0.009724:0.004543:0.010432:0.010432:0.004543:0.010272:0.011025:0.004543:0.010843:0.007807:0.004543:0.008765:0.011459:0.007442:0.010843:0.017485:0.010957:0.007875:0.010843:0.017577:0.009405:0.005250:0.004543:0.006437:0.007898:0.009085:0.011619:0.007556:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004543:0.005615:0.011756:0.004543:0.008811:0.011048:0.011071:0.007442:0.010820:0.010089:0.005615:0.017577:0.008811:0.006209:0.008948:0.005182:0.009724:0.004543:0.010432:0.010432:0.015043:0.004543:0.010845:0.006209:0.004543:0.011801:0.007533:0.014929:0.011619:0.011619:0.004109
patients . To identify the exact genomic breakpoint location, we designed two crRNAs :@0.117647:0.907821:0.857124:0.907821:0.857124:0.887448:0.117647:0.887448:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.018244:0.004497:0.004428:0.010866:0.011048:0.004428:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006506:0.009724:0.004428:0.006620:0.011299:0.009039:0.004428:0.009108:0.010089:0.009291:0.009106:0.006437:0.004428:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.004428:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.004428:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.004428:0.014518:0.009039:0.004428:0.011322:0.009039:0.007601:0.005615:0.009861:0.011596:0.009108:0.011391:0.004428:0.006437:0.014518:0.011048:0.004428:0.008994:0.007807:0.013376:0.015408:0.014586:0.007670:0.004109
404:@0.184346:0.900205:0.202592:0.900205:0.202592:0.888327:0.184346:0.888327:0.006082:0.006082:0.006082